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In familial amyloidotic polyneuropathy, TTR (transthyretin) vari-
ants are deposited as amyloid fibrils. It is thought that this process
involves TTR tetramer dissociation, which leads to partially
unfolded monomers that aggregate and polymerize into amyloid
fibrils. This process can be counteracted by stabilization of the
tetramer. Several small compounds, such as diclofenac, diflunisal
and flufenamic acid, have been reported to bind to TTR in vitro,
in the T4 (thyroxine) binding channel that runs through the TTR
tetramer, and consequently are considered to stabilize TTR. How-
ever, if these agents bind plasma proteins other than TTR,
decreased drug availability will occur, compromising their use as
therapeutic agents for TTR amyloidosis. In the present work, we
compared the action of these compounds and of new derivatives
designed to increase both selectivity of binding to TTR and
inhibitory potency in relation to TTR amyloid fibril formation. We
found two diflunisal derivatives that, in contrast with diclofenac,
flufenamic acid and diflunisal, displaced T4 from TTR in plasma
preferentially over binding to albumin and thyroxine binding
globulin. The same diflunisal derivatives also had a stabilizing
effect on TTR tetramers in plasma, as studied by isoelectric
focusing of whole plasma under semi-denaturing conditions. In
addition, by transmission electron microscopy, we demonstrated
that, in contrast with other proposed TTR stabilizers (namely
diclofenac, flufenamic acid and diflunisal), one of the diflunisal
derivatives tested efficiently inhibited TTR aggregation. Taken
together, our ex vivo and in vitro studies present evidence for
the selectivity and efficiency of novel diflunisal derivates as TTR
stabilizers and as inhibitors of fibril formation.
Key words: amyloid, diflunisal, neuropathy, stabilizer, thyroxine,
transthyretin.
INTRODUCTION
TTR (transthyretin) is a protein found in the plasma and
cerebrospinal fluid that is synthesized mainly by the liver and the
choroid plexus of the brain. The protein functions as a transport
protein carrying thyroid hormones, namely T4 (thyroxine), as well
as retinol through its interaction with retinol binding protein
[1]. More than 80 TTR variants have been described to date,
most of which are associated with different forms of hereditary
amyloidosis [2]. In these diseases, there is a misfolding of the TTR
molecule that leads to its aggregation and deposition as amyloid.
The deposition occurs systemically, but in many cases there is
a predominant involvement of the peripheral nervous system, as
occurs in FAP (familial amyloidotic polyneuropathy), the most
common form of TTR amyloidosis [3]. The most frequent TTR
variant implicated in FAP presents the substitution of valine for
methionine at position 30 of the polypeptide chain (TTR V30M).
Among the TTR variants described, around 10 are classified as
non-pathogenic, such as TTR T119M. This mutation has been
detected in heterozygotic carriers and in compound heterozygotic
individuals, i.e. carriers of both TTR T119M and TTR V30M. In
the latter case, TTR T119M is protective against the effects of
TTR V30M in the clinical phenotype [4,5].
The native TTR molecule is a homotetramer, formed by two
dimers. TTR possesses a high degree of β-pleated sheet structure
[6]. X-ray crystallography reveals that each dimer results from the
association of two monomers extending two β-sheets composed
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thyroxine binding globulin; TEM, transmission electron microscopy; TTR, transthyretin.
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of four β-strands, from each monomer, into two β-sheets of eight
β-strands. The dimer–dimer interface of the tetramer forms a
central hydrophobic channel that has two symmetry-related T4
binding sites presenting negative binding co-operativity [6].
Several investigators have proposed that the amyloidogenic
potential of the TTR variants is related to a decrease in the tetra-
meric stability of the protein [7]. For example, Altland and Winter
[8] demonstrated, by a combination of PAGE and IEF (isoelectric
focusing) under mild denaturation conditions, that amyloidogenic
TTR tetramers had a greater tendency to dissociate compared with
their wild-type counterparts. These authors also showed that sul-
phite exerts a stabilizing effect on the TTR tetramer, increasing
the tetramer/monomer ratio.
A recent study, investigating the dynamics of the aggregation
of TTR variants into amyloid fibrils, characterized different
molecular species in TTR fibrillogenesis that point to a model
involving several steps, namely dissociation of the tetramer and
polymerization of the resulting modified monomers into non-
fibrillar oligomers, leading to protofibrils that elongate further
into mature fibrils [9]. According to this proposed mechanism,
stabilization of the tetramer would be a fundamental step for the
inhibition of amyloid fibril formation. Several small compounds
sharing molecular structural similarities with T4 are candidate
ligands for the T4 binding sites, and have been proposed as
inhibitors of fibril formation in vitro [10,11].
In the present work we investigate, both in vitro and ex vivo:
(i) the TTR binding affinity and binding selectivity in plasma of
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Figure 1 Chemical structures of the compounds used
some previously reported fibril inhibitors, namely diflunisal, di-
clofenac and flufenamic acid, and some new derivatives designed
to show increased binding potencies compared with these well
known NSAIDs (non-steroidal anti-inflammatory drugs); and
(ii) the stabilization effects of the new and reference compounds
with regard to the tetrameric structure of TTR.
EXPERIMENTAL
Plasma samples
Whole blood from heterozygotic and homozygotic carriers of
TTR V30M, from heterozygotic carriers of TTR T119M, from
compound heterozygotic carriers of both TTR V30M and TTR
T119M, and from control individuals, was collected in the
presence of EDTA and centrifuged. The plasma was separated
and kept frozen at − 20 ◦C. The same procedure was used to
obtain plasma from TTR knockout mice carrying the human TTR
V30M gene [12].
Recombinant proteins
Recombinant wild-type TTR and the TTR variants TTR V30M,
TTR T119M and TTR Y78F were produced synthetically in a
bacterial expression system using Escherichia coli BL21 [13].
Plasma and recombinant TTRs were isolated according to a
previously described protocol [14]. The purity of the proteins
was assessed by SDS/PAGE and their concentration determined
using the Bio-Rad protein assay (Bio-Rad, Munich, Germany).
Chemical compounds studied for interaction with TTR
Diflunisal, diclofenac and flufenamic acid were from Sigma.
The diflunisal derivatives iododiflunisal (Mr 376.1) and bromo-
diflunisal (Mr 329.09), and the flufenamic acid derivative iodo-
flufenamic acid (Mr 407.13) (Figure 1), were synthesized as part
of a screening programme for TTR polymerization inhibitors
carried out at IIQAB-CSIC, Barcelona, and at the University
of Oviedo. After synthesis, the compounds were purified by
HPLC (99.9% purity) and characterized fully by NMR, MS
and elemental analysis. The synthetic procedure will be reported
elsewhere; details are available from G. Valencia on request. The
compounds were weighed and dissolved at approx. 10 mg/ml in
DMSO.
T4 binding assays
Qualitative studies of the displacement of T4 from plasma TTR
were carried out by incubation of samples of whole plasma (5 µl)
with [125I]T4 (specific radioactivity 1250 µCi/µg; concentration
320 µCi/ml; Perkin Elmer, Boston, MA, U.S.A.) in the presence
of different compounds (1 µl of a 10 mM solution), followed
by separation of the serum T4 binding proteins by PAGE in a
glycine/acetate buffer system as described previously [15]. The
gel was dried and subjected to phosphor imaging (Typhoon 8600;
Molecular Diagnostics, Amersham Biosciences) and the bands,
from four gels, were quantified using the program ImageQuant
version 5.1.
Competition of the various compounds with T4 for binding to
TTR was assayed quantitatively by a gel filtration procedure as
described previously [14,16]. Briefly, a solution of 30 nM TTR
in 0.1 M Tris, 0.1 M NaCl and 0.001 M EDTA buffer, pH 8.0,
was incubated with a trace amount of [125I]T4 plus increasing
concentrations of inhibitor (0–10 µM) overnight at 4 ◦C. [125I]T4
bound to TTR was separated from unbound T4 by gel filtration
chromatography through a column of Bio-Gel P6-DG (Bio-Rad,
Hercules, CA, U.S.A.). Non-specific binding was determined
using a 100 µM concentration of unlabelled T4. All samples
were run in duplicate. The data were analysed using GraphPad
Prism 2.0. Percentage binding was plotted against the logarithm
of the inhibitor concentration, and the EC50 was determined and
compared with the EC50 for T4. The EC50 T4/EC50 competitor ratio
reflects the relative inhibition potency.
TTR tetrameric stability assays by IEF under
semi-denaturing conditions
To perform this assay, 30 µl of plasma was incubated at 37 ◦C
for 1 h with 5 µl of a 10 mM solution of the compound to be tested.
For treatment with iododiflunisal, 10 different plasma samples
from TTR V30M carriers and controls were tested. The prepara-
tions were then subjected to native PAGE and the gel bands
containing TTR were excised and applied to an IEF gel. IEF
was carried out in the presence of 4 M urea, containing 5%
ampholytes, pH 4–6.5, at 1200 V for 6 h, essentially as described
previously [4,17]. These semi-denaturing conditions allow the
visualization of bands corresponding to the TTR monomer and
tetramer, and also to an oxidized form of the monomer. Proteins
were fixed with 20% (v/v) trichloroacetic acid and stained with
Coomassie Blue, and the dried gel was scanned (hp Scanjet 4470c;
Hewlett Packard) and subjected to densitometry (program UN-
SCAN-IT gel version 5.1).
Study of TTR aggregation by TEM (transmission electron
microscopy)
Soluble TTR Y78F at 2 mg/ml was dialysed against PBS and
incubated at 37 ◦C in the absence or presence of diflunisal, the
diflunisal derivative iododiflunisal or diclofenac at a molar ratio of
1:100. Control samples were incubated with DMSO. The protein
concentration was determined by the Lowry method [18]. After
48 h, samples were analysed by TEM.
For visualization by TEM, sample aliquots were diluted (1:50,
v/v) in PBS and negatively stained with 1% uranyl acetate. The
grids were visualized with a Zeiss microscope (model EM10C),
operated at 60 kV.
RESULTS
T4 competition studies
Our first approach to investigating the selectivity of TTR
stabilizers was to determine their capacity to compete with T4
c© 2004 Biochemical Society
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Figure 2 T4 binding gel electrophoresis of normal plasma incubated with
[125I]T4 and with various compounds as competitors
The migration of different plasma T4 binding proteins is indicated. The diflunisal derivatives are
indicated with an asterisk (*). IDIF, iododiflunisal; BrDIF, bromodiflunisal; IFLU, iododiflufenamic
acid. This gel is representative of other gels run in parallel.
for protein binding in plasma. The reference compounds tested
were selected on the basis of previous reports of their ability to
bind to TTR and inhibit fibril formation, and these were used as
parent compounds for the synthesis of new derivatives that may
show improved potency of binding to TTR. In particular, we
tested diflunisal, flufenamic acid and diclofenac as reference
compounds. We also assayed two new iodo derivatives (iodo-
diflunisal and iodoflufenamic acid) and a bromo derivative
(bromodiflunisal) (chemical structures are presented in Figure 1).
Since sulphite has been described as a stabilizing agent for
tetrameric TTR, we also included a sample treated with sulphite.
The results obtained for control plasma are shown in Figure 2. In
the absence of any drugs, three main proteins bound T4, as shown
in the control lane: the main binding protein was TBG (T4 binding
globulin), followed by albumin and TTR. Weaker TTR bands
were observed in the serum samples incubated with the drugs
(except that incubated with sulphite) compared with the TTR
band from control serum. This indicates that all compounds
tested mediated some inhibition of the binding of T4 to TTR.
Iodoflufenamic acid, a derivative of flufenamic acid, particularly
inhibited binding of T4 to TBG. Phosphor imaging analysis of
the gel demonstrated that the weakest inhibitors of T4 binding to
TTR were flufenamic acid and diclofenac, which presented 2–
4% inhibition. The most specific compounds to compete with T4
for the binding to TTR were diflunisal and its bromo derivative
bromodiflunisal, with inhibition of T4 binding of 70% and 75%
respectively; the most potent competitor was found to be the
iodo derivative, iododiflunisal, which inhibited 80–100% of T4
binding to TTR. A similar pattern of competition was obtained
when plasma samples from carriers of different TTR variants
(TTR V30M and TTR T119M) were analysed (results not shown).
These results allowed us to select compounds to be tested
subsequently for their potency in binding to TTR at binding
sites for T4. Competition binding studies were then performed
for determination of the EC50 for each compound. The relative
potency for the inhibition of binding of T4 was defined as the
ratio of EC50 T4/EC50 competitor. Figure 3 shows the competition
curves obtained for recombinant wild-type TTR (EC50 T4 35.4 +−
8.6 nM). Similar results were obtained for protein isolated from
normal serum (EC50 T4 16.8 +− 3.3 nM) (Table 1). The results
demonstrate that iododiflunisal, a derivative of diflunisal, was
the most potent inhibitor of T4 binding to TTR, with a relative
Figure 3 Displacement of T4 from wild-type recombinant TTR by diflunisal
derivatives
The curves were obtained using the various compounds indicated as competitive inhibitors.
IDIF, iododiflunisal; BrDIF, bromodiflunisal.
Table 1 Relative potency of drug inhibition of T4 binding to wild-type
recombinant TTR and to normal TTR isolated from plasma
EC50 T4/EC50 competitor




Flufenamic acid 0.22 –
Iododiflufenamic acid 0.15 0.003
Difluinsal 0.04 0.03
Diclofenac – 0.006
inhibition potency of 0.85; the other diflunisal derivative tested,
bromodiflunisal, was also a potent inhibitor of T4 binding, with
a relative inhibition potency of 0.53; both derivatives presented a
TTR binding affinity similar to that of T4. Flufenamic acid and its
derivative displayed similar potencies for binding to TTR, albeit
lower than that of iododiflunisal. Diclofenac and diflunisal were
the least potent competitors.
From the results obtained, we concluded that the diflunisal
derivative iododiflunisal was the most interesting and promising
compound in terms of the specific displacement of T4 from tetra-
meric TTR. We next compared this compound with T4 for binding
to TTR proteins isolated from the plasma of carriers of different
TTR variants, namely heterozygotic TTR V30M, heterozygo-
tic TTR T119M and compound heterozygotic carriers of TTR
V30M and TTR T119M. In all cases, the competition curves ob-
tained for iododiflunisal were very similar to the curves obtained
for unlabelled T4 (results not shown); the EC50 value for iodo-
diflunisal was lower than that of T4, demonstrating a slightly
higher affinity of iododiflunisal for each variant. In addition,
like T4, iododiflunisal bound to TTR from TTR V30M carriers
with lower affinity than to TTR from control individuals, and with
higher affinity to TTR from carriers of TTR T119M. Therefore the
TTR binding properties of iododiflunisal and T4 are very similar.
Effects on TTR stability
The effects of the various compounds on TTR stability were
investigated by IEF in the presence of 4 M urea. Plasma samples
from carriers of different TTR variants (heterozygotic and homo-
zygotic carriers of TTR V30M; heterozygotic carriers of TTR
c© 2004 Biochemical Society
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Figure 4 Analysis of plasma TTR by IEF in the presence of 4 M urea
Plasma samples from a control individual, from a heterozygotic carrier of TTR V30M and
from knockout mice expressing TTR V30M were incubated with various compounds. TTR was
then separated by PAGE and the isolated protein was analysed by IEF. The different molecular
species visualized in the IEF gel after Coomassie Blue staining are indicated. Note the stronger
bands corresponding to tetramers and the absence of monomer band in samples treated with
iododiflunisal (marked with an asterisk), which parallels the effect of sulphite. IDIF, iododiflunisal;
BrDIF, bromodiflunisal; IFLU, iododiflufenamic acid. These gels are representative of other gels
run in parallel.
T119M) and from controls were incubated with each of the com-
pounds and, after IEF, the band patterns and tetramer/monomer
ratios were compared. The results obtained with plasma from
control subjects and from heterozygotic carriers of TTR V30M
incubated with selected compounds are shown in Figure 4
(left and middle panels respectively). In parallel, plasma was
incubated with sulphite as a reference for the stabilization effect.
The incubation with sulphite also results in changes in the oxi-
dation state of the protein, which would explain the small
differences in the migration of the tetramer bands. Under the
conditions used, TTR presented a characteristic pattern of two
main bands, representing monomers (normal and oxidized forms),
and several bands of lower pI, representing different forms of
tetramers [17,19]. Under the conditions of the assay and in the
absence of drugs, the proportion of tetramer was found to be higher
in control plasma (75%) than in plasma from the heterozygotic
TTR V30M carrier (45%), as determined by densitometry
analysis of the gel. The results obtained for normal plasma incub-
ated with the various compounds demonstrated that in all cases
there was a slight increase of the percentage of tetramer in the pre-
sence of diclofenac (5% increase), whereas sulphite, diflunisal
and flufenamic acid had stronger stabilizing effects (15% in-
crease). However, when plasma was incubated with iododifluni-
sal or bromodiflunisal, only the tetrameric form of the protein
was detected. The effect was even more evident with plasma
from TTR V30M carriers, where the monomeric band disappeared
completely in the plasma incubated with iododiflunisal. A slight
increase in the proportion of tetramer (15% increase) was ob-
served for the plasma from the heterozygotic carrier of TTR V30M
incubated with sulphite, diflunisal or diclofenac. In contrast,
flufenamic acid did not increase the percentage of tetramer in
the TTR V30M sample. An effect of bromodiflunisal was not
evident for this sample. Therefore the results indicated that the
diflunisal derivatives tested (labelled with asterisks in Figure 4),
in particular iododiflunisal, had the most pronounced effects on
stabilization of the TTR tetramer. We performed a similar analysis
with plasma from TTR knockout mice carrying the human
gene for TTR V30M [12]. The stabilization effect of iododiflunisal
was again evident (Figure 4, right panel), in contrast with flufen-
amic acid and its derivative, which did not affect tetrameric
stability.
Effects on TTR aggregation
The effects of diflunisal and iododiflunisal on the aggregation of
TTR Y78F were compared. This variant is very prone to fibril
formation [20] and its aggregation pathway, under physiological
conditions (PBS, pH 7.4, 37 ◦C), has been characterized morpho-
logically by TEM (I. Cardoso and M. J. Saraiva, unpublished
work). Incubation of soluble TTR Y78F at 37 ◦C for 48 h led to
substantial aggregate formation (Figure 5B). If the period of
incubation was increased to 15 days, fibril formation could be vi-
sualized (results not shown). When the protein was pre-incubated
with iododiflunisal, no aggregates were visible (Figure 5C), and
only round particles resembling native TTR were observed.
In contrast, pre-incubation with diflunisal (Figure 5D) did not
prevent the formation of very large aggregates after 48 h, indi-
cating that this drug did not inhibit the aggregation of TTR Y78F.
Similarly to diflunisal, diclofenac (tested in a parallel experiment;
results not shown) did not inhibit TTR aggregation.
DISCUSSION
Various different proteins are involved in distinct forms of
amyloidosis. Despite the structural dissimilarities among the
various amyloidogenic precursor proteins, it has been proposed
that in each case native soluble proteins undergo partial unfolding,
leading to an amyloidogenic structure more prone to amyloid fibril
formation [21]. In particular, in the case of TTR amyloidosis, the
TTR tetramer dissociates into a non-native monomer (partially
unfolded) that has a tendency to form soluble aggregates that
can, in turn, seed amyloid fibril formation [22]. The conditions
leading to unfolding may be environmental, and thus related to
factors such as temperature, ionic strength, pH, oxidation potential
or others, or intrinsic to the protein, i.e. due to alterations in its
primary structure as a consequence of amino acid substitutions.
In TTR amyloidoses, both conditions might apply. While in
systemic senile amyloidosis [23] normal TTR is deposited as
amyloid, reflecting extrinsic causes of protein fibril formation, in
most cases of FAP, mutations are associated with the deposition
of TTR as amyloid fibrils [3]. The amino acid substitution in
each TTR variant determines structural alterations in the tetramer,
as demonstrated by X-ray diffraction analysis of the crystallized
mutant proteins. The most striking case is that of TTR L55P, a
highly amyloidogenic TTR variant [24]. Analysis of the crystal
structure of this variant revealed significant alterations in the
regions of dimer–dimer contacts, in accordance with the decreased
stability of the tetramer and consequently with its high amylo-
idogenicity. Although in most cases the structural alterations
induced by amino acid substitutions are not so evident, they still
might be sufficient to influence TTR tetramer stability and/or
interfere with the binding properties of TTR. On the other hand,
there are variants that are non-amyloidogenic and non-pathogenic,
such as TTR T119M. In this case, X-ray analysis of the TTR
T119M–T4 complex demonstrated that this variant presents alter-
ations in the T4 binding channel, including dimer–dimer contacts.
When compared with the wild-type protein or with amyloido-
genic TTR V30M, the TTR M119T variant shows novel atomic in-
teractions involving hydrogen bonds occurring within monomers,
dimers and the tetramer [25]. These additional interactions ex-
plain the greater stability of the variant and its protective effect
against the V30M mutation in compound heterozygotic carriers of
c© 2004 Biochemical Society
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Figure 5 Aggregation of TTR Y78F observed by TEM
(A) The initial preparation contains round particles resembling native TTR WT. (B) After 48 h at 37 ◦C, the protein aggregates and forms oligomers of different sizes. (C) Co-incubation with
iododiflunisal for 48 h at 37 ◦C inhibits TTR Y78F aggregation and results in structures similar to those observed in (A), whereas (D) co-incubation with diflunisal does not prevent aggregation, and
large aggregates are clearly visible. Scale bar = 100 nm.
TTR V30M and TTR T119M [4,5]. A recent study comparing the
misfolding energetics of TTR T119M and TTR V30M stressed
the importance of stabilization of the TTR tetramer in the process
of amyloid fibril formation [26]. Therefore one of the most likely
therapeutic approaches to the disease is to stabilize the TTR
protein, preventing its partial unfolding that triggers amyloid fibril
formation.
Several compounds have been reported to inhibit amyloid fibril
formation in vitro, as is the case for some NSAIDs and some
analogues [10,11,27,28]. For TTR amyloidoses it has been pro-
posed that these compounds exert their effect through binding to
T4 binding sites in TTR, as demonstrated by the crystal structures
of some of the complexes, in particular the TTR–diclofenac
complex [10,29] and more recently the TTR–diflunisal complex
[28]. Other approaches have been used to assess drug–TTR
complexes, including MS and isothermal calorimetry [27,30].
Most of these assays have been performed using isolated re-
combinant TTR in vitro, in the absence of physiological modu-
lating factors, namely other binding proteins. Characterization
of the interactions of the different compounds with TTR with
regard to specificity and selectivity, to confirm their preferential
binding to TTR over other binding proteins in plasma, in
particular the highly abundant albumin and the most potent T4
binding protein in human serum, TBG, is of paramount impor-
tance. Indeed, more recently, several studies have reported evalu-
ation of the selectivity of inhibitor binding to TTR in plasma by
immunoprecipitation of the TTR–inhibitor complexes and deter-
mination, by HPLC analysis, of the TTR fraction occupied
[27,31]. However, immunoprecipitation assays focus only on
the protein precipitated from treated plasma, and not the whole
untreated sample. Binding by proteins other than TTR may
lead to decreased availability of the drugs in plasma and hence
compromise their use as therapeutic agents for TTR amyloidosis.
We thus compared the effects of existing drugs and novel deri-
vatives in ex vivo assays employing whole plasma to assess their
binding to TTR at T4 binding sites and also their effects on
tetrameric stability.
Our qualitative and quantitative studies revealed that the
two diflunisal derivatives, iododiflunisal and bromodiflunisal,
showed high specificity and high affinity for binding to TTR, as
demonstrated by the T4 binding protein profile obtained after
electrophoresis of plasma. Both iododiflunisal and bromo-
diflunisal displaced T4 preferentially from TTR. The affinity
of these derivatives for TTR was also determined by in vitro
competition with T4 for binding to isolated recombinant TTR,
confirming the ex vivo results.
Since we did not find that diclofenac had a high binding affinity
for TTR, as compared with that of T4, the formation of a TTR–
diclofenac complex might be due to the specific conditions of
crystallization, and does not seem to be physiologically relevant.
The effect of the conditions of the assay, in particular with regard
to crystallization of the complex, has been also raised recently
in a study where the binding of small molecules to TTR was
characterized by MS [30].
Iododiflunisal and bromodiflunisal not only showed selective,
high-affinity binding to TTR, but also efficiently stabilized TTR
from dissociating into monomers in plasma from heterozygotic
TTR V30M carriers and from control subjects. This was demon-
strated by quantifying the resistance of plasma TTR to dissocia-
tion, after incubation with the compounds, in IEF experiments
[8]. Similar ex vivo results were obtained using plasma from
TTR V30M transgenic mice. In this ex vivo assay, diclofenac and
flufenamic acid, reported previously to be inhibitors of TTR fibril
formation, did not seem to stabilize the TTR tetramer effectively.
When we investigated the potency of our selected stabilizers
as inhibitors of amyloid fibril formation by TEM, the inhibitory
effect was very evident; in these studies we used TTR Y78F,
a mutant protein with a high tendency to form amyloid fibrils.
This mutant TTR has revealed epitopes similar to those present
in fibrils, as assessed using monoclonal antibodies specific for
TTR amyloid fibrils, suggestive of the structure of an early
intermediate in the fibrillogenesis pathway [20]. Iododiflunisal
inhibited TTR aggregation, as demonstrated by TEM, contrary
to what was found for the protein incubated with diflunisal (no
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inhibition). Under the assay conditions, iododiflunisal prevented
the formation of TTR oligomers, considered to be one of the
first steps of TTR fibrinillogenesis in vitro [9]. Given that this
is a multi-step process, the possibility cannot be excluded that
diflunisal or other compounds may act on different stages of fibril
formation.
Taken together, our ex vivo and in vitro studies present evidence
for the selectivity and efficiency of novel diflunisal derivatives as
TTR stabilizers and inhibitors of fibril formation. The criteria
of (i) ex vivo selectivity of binding to TTR at T4 binding sites,
(ii) ex vivo TTR tetrameric stabilization, and (iii) definition of
the inhibitory step of fibrillogenesis, must be taken into consi-
deration in the further testing of drugs with therapeutic interest
for the treatment of TTR amyloidosis.
The evaluation of iododiflunisal as a TTR stabilizer will proceed
with animal studies. Initial testing of the effect of iododiflunisal
on TTR from mouse plasma ex vivo showed a stabilization effect
similar to that observed for TTR from human plasma. This is
highly encouraging for the pursuit of in vivo studies using selected
diflunisal derivatives and for applying the same methodology
to screening for stabilizers of tetrameric TTR as potential thera-
peutics for TTR amyloidoses.
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